Announcements Trials
Browse Landscape

Status

Recruiting 15Completed 13Unknown 8Terminated 3Not yet recruiting 3Active not recruiting 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 20Observational 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Breast Neoplasms 138Neoplasms 134Lung Neoplasms 68Prostatic Neoplasms 67Carcinoma, Non-Small-Cell Lung 58Colorectal Neoplasms 45Multiple Myeloma 37Pancreatic Neoplasms 33Melanoma 32Head and Neck Neoplasms 30Brain Neoplasms 30Neoplasm Metastasis 28Ovarian Neoplasms 27Liver Neoplasms 27Carcinoma, Hepatocellular 27Leukemia, Myeloid, Acute 25Colonic Neoplasms 23Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Lymphoma 20Leukemia, Lymphocytic, Chronic, B-Cell 20Esophageal Neoplasms 20Carcinoma, Renal Cell 20Lymphoma, Non-Hodgkin 19Urinary Bladder Neoplasms 18Stomach Neoplasms 18Glioblastoma 18Uterine Cervical Neoplasms 17Sarcoma 17Lymphoma, Follicular 17Lymphoma, Large B-Cell, Diffuse 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Observational × Non-Muscle Invasive Bladder Neoplasms × Clear all
NCT06026332 2026-02-17

ABLE-41

Ferring Pharmaceuticals

Terminated
202 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT04412070 2025-11-21

ALU

Hopital Foch

Terminated
20 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT01314664 2015-06-12

A Prospective Registry to Assess the Effectiveness and Local Tolerability of Intravesical Valrubicin in Subjects With Non-muscle Invasive Bladder Cancer (NMIBC)

Endo Pharmaceuticals

Terminated
15 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡